We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Read MoreHide Full Article
Key Takeaways
Neurocrine posted 39% revenue growth and a 73% rise in adjusted EPS in Q2.
Ingrezza sales rose 15%, prompting Neurocrine to raise its 2026 sales guidance to $2.825-$2.875 billion.
Crenessity and Vykat XR are broadening growth, while higher R&D and SG&A spending adds pressure.
Neurocrine Biosciences (NBIX - Free Report) delivered a better-than-expected second quarter, with revenues and adjusted earnings per share topping the Zacks Consensus Estimate. The company also raised its 2026 Ingrezza sales outlook, reinforcing the role of its flagship therapy in near-term growth.
The next test is whether prescription momentum, Crenessity's launch and Vykat XR can keep widening the revenue base as research and commercial spending rises. That balance matters because Ingrezza remains Neurocrine's main revenue engine even as newer products broaden the portfolio.
NBIX Delivers a Strong Q2 Beat
Second-quarter revenues increased 39% year over year to $959 million, above the Zacks Consensus Estimate of $901.5 million. Adjusted earnings of $2.85 per share rose 73% and beat the consensus estimate of $2.26.
The beat was broad-based. Ingrezza sales reached $716 million versus the $628.6 million consensus mark, while Crenessity generated $184 million compared with the $170.8 million estimate. Vykat XR added $54 million from May 18 through quarter-end, giving Neurocrine contributions from all three marketed therapies.
Neurocrine Raises the Bar for Ingrezza
Ingrezza sales increased 15% in the second quarter and 17% in the first half of 2026 to $1.4 billion. Neurocrine cited double-digit prescription volume growth, record new prescriptions and continued access covering about 70% of Medicare lives.
Management raised 2026 Ingrezza net product sales guidance to $2.825-$2.875 billion from $2.7-$2.8 billion, implying roughly 13% growth at the midpoint. Neurocrine estimates that tardive dyskinesia affects about 800,000 U.S. patients, with roughly 10% receiving a VMAT2 inhibitor. Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) markets competing Austedo and Austedo XR in tardive dyskinesia and Huntington's disease chorea.
Neurocrine Biosciences, Inc. Price and EPS Surprise
Crenessity generated $337 million in first-half 2026 sales, up about 400% year over year and already above its $301 million total for 2025. About 15% of the estimated diagnosed classic congenital adrenal hyperplasia population has been prescribed the drug, and its prescriber base has nearly tripled.
Vykat XR contributed $54 million in reported second-quarter sales after the Soleno acquisition closed in May, while unaudited pro forma full-quarter sales were $94 million. Neurocrine expects launch-related discontinuations to largely work through during the third quarter and anticipates sequential sales growth beginning in the fourth quarter.
Neurocrine Is Spending More To Scale
Adjusted research and development expenses rose 24% to $276.1 million, reflecting investment across a broader development portfolio. Adjusted selling, general and administrative expenses increased 20% to $304.9 million as Neurocrine expanded commercial support for Ingrezza, Crenessity and Vykat XR.
The company also raised 2026 adjusted research and development guidance to $1.14-$1.19 billion and selling, general and administrative guidance to $1.325-$1.35 billion. Bristol Myers Squibb (BMY - Free Report) already markets Cobenfy for adults with schizophrenia, a market relevant to Neurocrine's phase III direclidine program and its expanding research investment.
NBIX Signals Temper Q2 Optimism
The second-quarter beat, higher Ingrezza guidance and growing rare-disease portfolio support the revenue story, but higher operating investment and execution risks keep the outlook balanced. Vykat XR retention, Ingrezza pricing exposure and pipeline delivery remain important variables as Neurocrine scales.
NBIX currently carries a Zacks Rank #3 (Hold), which is less favorable than the #1 and 2 (Buy) ranks that Zacks Style Scores are designed to complement most effectively. Its Growth Score of A and VGM Score of A indicate favorable growth and blended style characteristics, while its Value Score of B is also constructive. The Momentum Score of D points to weaker momentum characteristics, tempering the otherwise favorable Style Score mix.
View the Zacks #1 Rank List
Image: Bigstock
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Key Takeaways
Neurocrine Biosciences (NBIX - Free Report) delivered a better-than-expected second quarter, with revenues and adjusted earnings per share topping the Zacks Consensus Estimate. The company also raised its 2026 Ingrezza sales outlook, reinforcing the role of its flagship therapy in near-term growth.
The next test is whether prescription momentum, Crenessity's launch and Vykat XR can keep widening the revenue base as research and commercial spending rises. That balance matters because Ingrezza remains Neurocrine's main revenue engine even as newer products broaden the portfolio.
NBIX Delivers a Strong Q2 Beat
Second-quarter revenues increased 39% year over year to $959 million, above the Zacks Consensus Estimate of $901.5 million. Adjusted earnings of $2.85 per share rose 73% and beat the consensus estimate of $2.26.
The beat was broad-based. Ingrezza sales reached $716 million versus the $628.6 million consensus mark, while Crenessity generated $184 million compared with the $170.8 million estimate. Vykat XR added $54 million from May 18 through quarter-end, giving Neurocrine contributions from all three marketed therapies.
Neurocrine Raises the Bar for Ingrezza
Ingrezza sales increased 15% in the second quarter and 17% in the first half of 2026 to $1.4 billion. Neurocrine cited double-digit prescription volume growth, record new prescriptions and continued access covering about 70% of Medicare lives.
Management raised 2026 Ingrezza net product sales guidance to $2.825-$2.875 billion from $2.7-$2.8 billion, implying roughly 13% growth at the midpoint. Neurocrine estimates that tardive dyskinesia affects about 800,000 U.S. patients, with roughly 10% receiving a VMAT2 inhibitor. Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) markets competing Austedo and Austedo XR in tardive dyskinesia and Huntington's disease chorea.
Neurocrine Biosciences, Inc. Price and EPS Surprise
Neurocrine Biosciences, Inc. price-eps-surprise | Neurocrine Biosciences, Inc. Quote
NBIX Adds Rare-Disease Growth Engines
Crenessity generated $337 million in first-half 2026 sales, up about 400% year over year and already above its $301 million total for 2025. About 15% of the estimated diagnosed classic congenital adrenal hyperplasia population has been prescribed the drug, and its prescriber base has nearly tripled.
Vykat XR contributed $54 million in reported second-quarter sales after the Soleno acquisition closed in May, while unaudited pro forma full-quarter sales were $94 million. Neurocrine expects launch-related discontinuations to largely work through during the third quarter and anticipates sequential sales growth beginning in the fourth quarter.
Neurocrine Is Spending More To Scale
Adjusted research and development expenses rose 24% to $276.1 million, reflecting investment across a broader development portfolio. Adjusted selling, general and administrative expenses increased 20% to $304.9 million as Neurocrine expanded commercial support for Ingrezza, Crenessity and Vykat XR.
The company also raised 2026 adjusted research and development guidance to $1.14-$1.19 billion and selling, general and administrative guidance to $1.325-$1.35 billion. Bristol Myers Squibb (BMY - Free Report) already markets Cobenfy for adults with schizophrenia, a market relevant to Neurocrine's phase III direclidine program and its expanding research investment.
NBIX Signals Temper Q2 Optimism
The second-quarter beat, higher Ingrezza guidance and growing rare-disease portfolio support the revenue story, but higher operating investment and execution risks keep the outlook balanced. Vykat XR retention, Ingrezza pricing exposure and pipeline delivery remain important variables as Neurocrine scales.
NBIX currently carries a Zacks Rank #3 (Hold), which is less favorable than the #1 and 2 (Buy) ranks that Zacks Style Scores are designed to complement most effectively. Its Growth Score of A and VGM Score of A indicate favorable growth and blended style characteristics, while its Value Score of B is also constructive. The Momentum Score of D points to weaker momentum characteristics, tempering the otherwise favorable Style Score mix.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.